IXICO awarded two further contracts in Huntington’s disease

IXICO today announces that it has been awarded contracts for two separate clinical trials in Huntington’s disease (HD) with top 15 pharmaceutical companies. These contracts are in addition to a third clinical study already underway in HD which is developing into an important indication specialty for IXICO.

HD is a rare genetic neurodegenerative disorder that affects the patient’s normal movement, cognition and behaviour. HD is more common in people of Western European descent than in those of Asian or African ancestry, affecting approximately 5-7 people per 100,000 in Western countries.

By |2017-10-11T12:13:33+00:0022 May 2014|Contracts|